<div class="infobox infobox-protein">
<div class="infobox-header">NMNAT1 Protein</div>
<div class="infobox-row"><span class="infobox-label">Protein Name</span><span class="infobox-value">Nicotinamide Mononucleotide Adenylyltransferase 1</span></div>
<div class="infobox-row"><span class="infobox-label">Gene</span><span class="infobox-value">[NMNAT1](/genes/nmnat1)</span></div>
<div class="infobox-row"><span class="infobox-label">UniProt ID</span><span class="infobox-value">[Q9HAN9](https://www.uniprot.org/uniprot/Q9HAN9)</span></div>
<div class="infobox-row"><span class="infobox-label">Molecular Weight</span><span class="infobox-value">~31.9 kDa (279 aa)</span></div>
<div class="infobox-row"><span class="infobox-label">Subcellular Localization</span><span class="infobox-value">Nucleus</span></div>
<div class="infobox-row"><span class="infobox-label">Protein Family</span><span class="infobox-value">NMN adenylyltransferase family</span></div>
<div class="infobox-row"><span class="infobox-label">Associated Diseases</span><span class="infobox-value">Leber congenital amaurosis type 9, axon degeneration</span></div>
</div>
<div class="infobox infobox-protein">
<div class="infobox-header">NMNAT1 Protein</div>
<div class="infobox-row"><span class="infobox-label">Protein Name</span><span class="infobox-value">Nicotinamide Mononucleotide Adenylyltransferase 1</span></div>
<div class="infobox-row"><span class="infobox-label">Gene</span><span class="infobox-value">[NMNAT1](/genes/nmnat1)</span></div>
<div class="infobox-row"><span class="infobox-label">UniProt ID</span><span class="infobox-value">[Q9HAN9](https://www.uniprot.org/uniprot/Q9HAN9)</span></div>
<div class="infobox-row"><span class="infobox-label">Molecular Weight</span><span class="infobox-value">~31.9 kDa (279 aa)</span></div>
<div class="infobox-row"><span class="infobox-label">Subcellular Localization</span><span class="infobox-value">Nucleus</span></div>
<div class="infobox-row"><span class="infobox-label">Protein Family</span><span class="infobox-value">NMN adenylyltransferase family</span></div>
<div class="infobox-row"><span class="infobox-label">Associated Diseases</span><span class="infobox-value">Leber congenital amaurosis type 9, axon degeneration</span></div>
</div>
NMNAT1 (Nicotinamide Mononucleotide Adenylyltransferase 1) is the nuclear isoform of the NMNAT enzyme family, which catalyzes the final step in NAD+ biosynthesis: the adenylylation of nicotinamide mononucleotide (NMN) to produce NAD+. NAD+ is an essential cofactor for hundreds of enzymatic reactions including those mediated by [sirtuins](/proteins/sirt1-protein), [PARPs](/proteins/parp1-protein), and CD38. NMNAT1 is encoded by the [NMNAT1](/genes/nmnat1) gene on chromosome 1p36.22, and its activity in the nucleus is critical for maintaining the NAD+ pool required for DNA repair, chromatin remodeling, and transcriptional regulation.[@lau2009] Loss-of-function mutations in NMNAT1 cause Leber congenital amaurosis type 9 (LCA9), a severe inherited retinal dystrophy, while gain-of-function studies demonstrate that NMNAT overexpression potently delays Wallerian degeneration and axon loss in multiple neurodegenerative models.[@mack2001]
NMNAT1 is a 279-amino-acid protein that functions as a homohexamer. Each monomer adopts a Rossmann-fold topology characteristic of nucleotide-binding enzymes, with a central parallel beta-sheet flanked by alpha-helices. The active site lies at the monomer-monomer interface and coordinates both NMN and ATP substrates through a network of conserved residues including Trp169, His24, and Arg197.[@zhou2002] The catalytic mechanism involves a ping-pong bi-substrate reaction: ATP first donates its AMP moiety to a histidine residue, forming a covalent enzyme-AMP intermediate, followed by transfer of AMP to NMN to yield NAD+ and pyrophosphate (PPi).[@zhou2002]
Crystal structures of human NMNAT1 reveal that disease-causing LCA9 mutations (e.g., E257K, R237C, V9M) cluster at the oligomerization interface or substrate-binding pocket, reducing catalytic efficiency or destabilizing the hexameric assembly.[@koenekoop2012] NMNAT1 contains a nuclear localization signal (NLS) near the N-terminus that directs it exclusively to the nucleus, distinguishing it from [NMNAT2](/proteins/nmnat2-protein) (cytoplasmic/axonal) and [NMNAT3](/proteins/nmnat3-protein) (mitochondrial).
NMNAT1 is the primary enzyme responsible for nuclear NAD+ synthesis. Nuclear NAD+ is consumed by:
The neuroprotective role of NMNAT1 was revealed through the Wallerian degeneration slow (WldS) mouse, which carries a spontaneous chromosomal triplication creating a chimeric gene encoding a fusion of NMNAT1 with the N-terminal 70 amino acids of UBE4B (Ube4b/NMNAT1).[@mack2001] The WldS protein is redirected from the nucleus to axons and synapses, where it substitutes for the labile [NMNAT2](/proteins/nmnat2-protein), the endogenous axonal NMNAT isoform. Upon axotomy, wild-type axons degenerate within hours because the short-lived NMNAT2 is rapidly depleted, triggering activation of [SARM1](/proteins/sarm1-protein) — a NADase that catastrophically consumes axonal NAD+.[@essuman2017] WldS-derived NMNAT1 is more stable than NMNAT2 and prevents SARM1 activation, delaying Wallerian degeneration for weeks. This discovery established the NMNAT-SARM1 axis as a central mechanism in programmed axon destruction.
NMNAT1 is highly expressed in retinal photoreceptors and retinal pigment epithelium. It maintains the high NAD+ demand of these metabolically active cells, supporting phototransduction, outer segment renewal, and resistance to oxidative damage from chronic light exposure.[@koenekoop2012]
Biallelic loss-of-function mutations in NMNAT1 cause LCA9, one of the most severe forms of inherited retinal dystrophy, with profound vision loss from infancy.[@koenekoop2012] Over 40 pathogenic variants have been identified, including missense mutations at the active site (E257K), oligomerization interface (R237C), and protein stability determinants (V9M). The retinal specificity likely reflects the exceptionally high metabolic demand of photoreceptors, which have among the highest NAD+ consumption rates of any cell type. Mouse models carrying hypomorphic Nmnat1 alleles recapitulate progressive photoreceptor degeneration with outer nuclear layer thinning.[@greenwald2016]
Although NMNAT1 is normally nuclear, its enzymatic activity becomes neuroprotective when redirected to axons (as in the WldS model). This has major implications for diseases featuring axon degeneration:
Brain NAD+ levels decline progressively with aging and are further reduced in [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). This decline reflects both increased consumption (hyperactive PARP1, elevated CD38) and decreased synthesis. NMNAT1 expression itself is reduced in aged rodent brain, contributing to nuclear NAD+ depletion and impaired DNA repair capacity.[@imai2014] Restoring NAD+ through precursor supplementation (NMN, NR) or NMNAT overexpression has emerged as a major therapeutic strategy.
Because NMNAT1 catalyzes the conversion of NMN to NAD+, its activity is essential for the efficacy of NMN supplementation strategies. Clinical trials of nicotinamide riboside (NR) and NMN in Alzheimer's disease and aging are ongoing, and their benefit depends on adequate NMNAT expression in target tissues.[@imai2014]
Small-molecule inhibitors of [SARM1](/proteins/sarm1-protein) (the downstream effector of NMNAT2 loss) are in preclinical development for axonal neuropathies. These agents functionally mimic NMNAT overexpression by preventing NAD+ catastrophic consumption.[@essuman2017]
AAV-mediated delivery of wild-type NMNAT1 to the retina has shown efficacy in mouse models of LCA9, with photoreceptor rescue and visual function restoration when delivered early.[@greenwald2016] Phase I clinical trials are being planned.